Loading patent…
AssigneesThe Rockefeller University, Children's Hospital Medical Center
InventorsPaul Greengard, David Repaske, Gretchen Snyder
Estimating the term…
The present invention provides methods and compositions for modulating the activity of phosphodiesterase 1B (PDE1B) in intracellular signaling pathways, including but not limited to, dopamine D1 intracellular signaling pathways. The invention also provides methods and compositions for modulating the activities of intracellular signaling molecules, including, but not limited to, DARPP-32 and GluR1 AMPA receptor, via modulation of PDE1B. The invention also provides pharmaceutical compositions and methods of screening for compounds that modulate PDE1B activity. The invention also provides methods of treating or ameliorating the symptoms of a disorder, including but not limited to a PDE1B-related disorder or a dopamine D1 receptor intracellular signaling pathway disorder, by administering a modulator of PDE1B, preferably, but not limited to, an inhibitor of PDE1B or an agent that decreases the production of PDE1B.
An in vitro method of identifying a compound that inhibits phosphodiesterase 1 B (“PDE1B”) activity in a dopamine D1 receptor intracellular signaling pathway by binding to or altering the expression of PDE1B in a cell or tissue expressing dopamine D1 receptor comprising:
An in vitro method of identifying a compound that inhibits phosphodiesterase 1 B (“PDE1B”) activity in a dopamine D1 receptor intracellular signaling pathway by binding to or altering the expression of PDE1B and Thr34 of DARPP-32 phosphorylation in a cell or tissue expressing dopamine D1 receptor comprising:
Dependencies are inferred from the claim text.